While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > BUSINESS
BUSINESS
- Takara Bio: Research Reagents Drive Growth in Sales, Profits
November 7, 2011
- Kissei: Pharm. Sales Down 0.5%, Profits Up
November 7, 2011
- ASKA: Sales Down 8.4% Due to Rebound from a Spike at Last Fiscal Year End
November 7, 2011
- Breast Cancer Project Selected for Health Science Research Grant: 3-D Matrix
November 7, 2011
- Pharmacies Satisfied, Wholesalers Dissatisfied with Price Negotiations: Yano Research Survey
November 7, 2011
- CMIC: Sales, Profits Up Driven by CRO Business
November 7, 2011
- Sales of Actos Down 22% in 1st Half Due to Bladder Cancer Concerns, Generic Competition: Takeda
November 5, 2011
- Qol Decides to Discontinue “Dispensing Points” in March 2012
November 4, 2011
- Ono President Says Glactiv to “Still Show Advantage of Early Release”
November 4, 2011
- Asahi Kasei Pharma’s Apr-Sep Sales Up 6% Due to Doubled Recomodulin Sales
November 4, 2011
- Once-Yearly Dosing Osteoporosis Agent Starts PIII Study: Asahi Kasei Pharma
November 4, 2011
- FDA Assigns Action Date of Jan 25, 2012 for Takeda’s Alogliptin
November 4, 2011
- Sales of Medical & Pharmaceutical Business Increased 2.4% Driven by New Drugs: Teijin
November 4, 2011
- Astellas: Sales, Profits Up in First Half Driven by Vesicare
November 4, 2011
- Eisai Announces Double-digit Declines in 1st-Half Sales, Profits
November 4, 2011
- Complaints of Side Effects from Lyrica Up Sharply: Nextit Research
November 4, 2011
- Miraca HD: Sales, Profits Up due to Addition of Innogenetics NV
November 4, 2011
- Kaken: Mainstay Products, Generics Pull Business
November 4, 2011
- Santen Sends Expert Researchers to US, Europe to Assess Candidate Compounds for In-licensing
November 4, 2011
- Anti-androgen Drug MDV3100 Significantly Improves OS in PIII AFFIRM Trial: Astellas
November 4, 2011
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…